Page Title
We live product development – transforming ground-breaking ideas into life-saving medication.

News

Press release on the results of a novel tuberculosis vaccine tested in a large phase III trial against severe respiratory infectious diseases

The course of respiratory infectious disease pandemics, will strongly depend on how quickly medications or specific vaccines against the pathogens are available. Researchers wanted to investigate in a phase III trial whether the vaccine candidate VPM1002 is also protective against an infection with the novel SARS-CoV-2. The large-scale study has been carried out at several hospitals in Germany and included older people that are susceptible to severe course of the disease. Read about the results here!

Prime update: visit to the East African clinical sites

We are pleased that after the long COVID lockdown we were also able to visit the East African sites to touch base and to discuss the conduct of the trial and potential improvements. We thank all centres for their warm welcome and their hospitality during our stay and hope to meet more often in person again.

Results of SAKK 06/14 trial with VPM1002BC as treatment for non-muscle-invasive bladder cancer have been published in European Urology Oncology

The phase I/II clinical trial data with VPM1002BC, a genetically modified bacillus Calmette-Guérin (BCG) strain, has been published in European Urology Oncology. Even three years after the treatment start, almost half of the patients remained recurrence-free. We thank all patients, colleagues, and collaborators for their contributions. Please click here to read the publication.

Scroll to Top